Morgan Stanley Maintained an Overweight Rating on AbbVie (ABBV)

AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and a $250 price target on AbbVie, in light of the company’s recent acquisition announcement.

Recently, AbbVie announced its intention to acquire Capstan Therapeutics, a clinical-stage biotechnology firm specializing in in-vivo cell engineering through RNA delivery platforms, for up to $2.1 billion in cash, contingent upon standard closing conditions. The company has a robust financial foundation, including a 71% gross profit margin and 5.45% year-over-year revenue growth, making AbbVie strategically positioned to integrate this acquisition and advance its innovation pipeline.

As part of the agreement, AbbVie Inc. (NYSE:ABBV) will gain access to CPTX2309, an in-vivo anti-CD19 CAR-T candidate currently undergoing Phase 1 clinical evaluation for B cell-mediated autoimmune disorders. The acquisition also includes Capstan’s proprietary lipid nanoparticle (LNP) platform, which enables targeted RNA delivery for the in-vivo engineering of specific cell populations.

According to Morgan Stanley, the deal represents a constructive step forward for AbbVie, enhancing its technological capabilities and reinforcing its pipeline in early-stage immunological research.

This move complements AbbVie’s previously outlined growth agenda, which forecasts expansion through 2032, with recent technology acquisitions offering critical optionality and pipeline diversification.

AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company focused on the discovery, development, and commercialization of therapies including immunology, oncology, neuroscience, virology, and ophthalmology.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Dow 20 Stocks List: Ranked By Hedge Fund Bullishness Index and 10 Unstoppable Dividend Stocks to Buy Now.

Disclosure. None.